Combating complexity: Partnerships in personalized medicine

Personalized Medicine

Volumn 10, Issue 4, 2013, Pages 387-396

  Pothier, Kristin ^a   Gustavsen, Gary ^a  

^a Health Advances   (United States)

Author keywords

commercialization; diagnostics; life science; oncology; outsourcing; partnership; personalized medicine; targeted therapy

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; TRASTUZUMAB;

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CAPILLARY ELECTROPHORESIS; CHRONIC MYELOID LEUKEMIA; HUMAN; INTRACELLULAR SIGNALING; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW;

EID: 84878910039     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.28     Document Type: Review

References (17)

1. Corbett MF. The Outsourcing Revolution: Why it Makes Sense and How to Do it Right. Dearborn Trade Publishing, IL, USA (2004).
2. Kutscher B. Expertise on call: annual outsourcing report shows providers of all sizes continue to pursue arrangements that offer savings for their revenue-strapped operations. Mod. Healthc. 42(36), 20, 22, 24-27 (2012).
3. .Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat. Med. 18(3), 349-351 (2012).
4. Ciftlik AT, Lehr HA, Gijs MA. Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs. Proc. Natl Acad. Sci. USA 110(14), 5363-5368 (2013).
5. Vo BT, Morton D, Komaragiri S, Millena AC, Leath C, Khan SA. TGF-b effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation ofPI3K/AKT/mTOR pathway. Endocrinology 154(5), 1768-1779 (2013).
6. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 14(2), e60-e69 (2013).
7. Chen G, Noor A, Kronenberger P, Teugels E, Umelo IA, De Greve J. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS ONE 8(3), e59708 (2013).
8. Zhang YJ, Gallis B, Taya M, Wang S, Ho RJ, Sasaki T. pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PLoS ONE 8(3), e59086 (2013).
9. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1(8), 1223-1225 (2012).
10. Kubo N, Wu D, Yoshihara Y, Sang M, Nakagawara A, Ozaki T. Co-chaperon DnaJC7/TPR2 enhances p53 stability and activity through blocking the complex formation between p53 and MDM2. Biochem. Biophys. Res. Commun. 430(3), 1034-1039 (2013).
11. Li W, Tsen F, Sahu D, Bhatia A, Chen M, Multhoff G, Woodley DT. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. Int. Rev. Cell Mol. Biol. 303, 203-235 (2013).
12. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3,-PDGFRA and-KIT isoforms. Mol. Cancer 12(1), 19 (2013).
13. Goncalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. J. Natl Compr. Canc. Netw. 11(2), 174-182 (2013).
14. Dias MM, McKinnon RA, Sorich MJ. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics 13(8), 889-899 (2012).
15. Gerrard G, Mudge K, Foskett P et al. Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization. Am. J. Hematol. 87(7), 717-720 (2012).
16. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3), 179-190 (2010).
17. Hornberger J, Chien R, Krebs K, Hochheiser L. US insurance program's experience with a multigene assay for early-stage breast cancer. Am. J. Manag. Care 17(5), e194-e202 (2011).